Member Info for Quickdraw18

Did any of the Gov grant money go to commercial organisations? I see Oxford Uni and London Imperial in article.

Hi just here for Hemo, as the company are an early stage bio company they will require cash for many years to invest in new treatment candidates. Don't see Hemogenyx's issuing a dividend for 5+ years. Given their potential pipeline they can create significant more shareholder wealth by investing profits into future developments.

Personally i see little value in dividends unless one is a pension fund or has a large holding in a taxable account.
When a dividend is issued (e. g. 0.2%) this percentage is taken off the share price, so no actual additional value is created for shareholders. Growth stocks tend not to issue dividends.. My best growth stock returned me 600% gain over 6 years, after 4 years i started receiving dividend of 0.1% (chicken feed)

The other dividend i have recived was Royal Mail, waited 6 months for 7%, it was on the day that I learnt the SP will always drop by same amount (7%) . I waited 2 months for the dividend, in mean time shate price had fallen by about 30%.

Ye the x 4 test is linked to the AstraZeneca lab. New lab equipment can test 384 samples at a time compared to 96 which appears standard for PCR.

I thought you implying doubts Novacyt could sell product based on Co-Diagnostics struggling to sell theirs?

My point was Novacyts test works and Co-Diagnostics only picks up more sever cases, x13 load more than Nova.

With the way UK and USA are handling COVID I sadly see huge demand. As mentioned previously, within 3 weeks Novacyt could have a 18>22 min antigen test that doesn't rely on in demand extraction reagents. This could set them leagues apart from competition. I've seen a 3 hour test, but none quick which can be proceeded on 96 chamber PCR unit or higher. I exclude the single test Abbott 10 min test

In last RNS said new test would be x4 faster. Current test takes up to 90 mins and as as quick as 75 mins. So new test should be between 18> 22.5mins

Luciano the Abbott antigen test which takes 10 mins but only test one sample atva time has had a 50% failure rate.
I retract my statement on Co-Diagnostics test being faulty, their test detects a very high viral load, 4,290 copies/mL compared to Novacyts 330 copies/mL*. Note Novacy don't have the lowest load, but the performance of test is a mix of sensitivity and load. Where Abbott preformed better on load some of their tests have had 50% sensitivity.

Main problem with any america antigen or antibody test is emergency approval, required self declare test results with no verification. Cowboy market. I was in with Chembio Diagnostics but got out with 40% for this risk. FDA bring end to this issue.

https://mobile.labmedica.com/?option=com_mobile_article&Itemid=294782401

https://www.biocentury.com/article/304801/biocentury-is-providing-this-story-for-free-given-the-urgent-need-for-information-about-the-covid-19-crisis-for-more-analysis-sign-up-for-our-daily-email

Glad to hear you got out of Co-Diagnostics in time. I agree with you on Co but not on Novacyt. Co-Diagnostics sales are 6 times lower than Novacyt as they have a faulty test. Novacyt don't have this issue, have the sales and a clear capacity plan, plus a 22nin test coming. I expect we will get a sales update at end of month or will be tied in with announcement of new test in early June

Co-Diagnostics have MADE 6m tests and recived $18m in sales in total. Works out at $3 a kit. Novacyt kit $10.50. It's more likely Co-Diagnostics have 3+m in sellable kits, I've read their tests are junk.

Co-Diagnostics -
. $18m COVID sales
. $214k 2019 sales
. $607m company Value

Novacyt -
. $108m covid sales
. $15.7m 2019 sales
. $282m company Value

Both companies launched products in Feb. America ?? ????

My view is Hemogenyx have limited resources so they are identifying target treatments in stages (ALL, AML, lulus and now COVID). Once they have identified a treatment they spin out further development, testing and commercialisation to a partner and continues to seek out further conditions. They plan to apply their mice, Bispecific antibodies and Hu-PHEC cells to target auto immune conditions and blood cancers.

A flurry of mice sales should help validate Hemogenyx's own internal testing on mice and boost confidence in their existing candidates ALL, AML and Lupus and future candidates

I'll second that manifesto, also Sorrento have identified and tested in petri dish one antibody and say theh need a ****tail.

Hemo will be testing their CIVID specific antibodies in humanised mice.

One other thing to note, antibodies can play havoc with the bodies immune system. Remember those whose heads swelled few years back? That was due to a anybody reaction. Sorrento are picking thermo Antybodies from a catalog of known antibodies, Hemo are using antibodies in recovered COVID sufferers. Specific and will have a much higher chance of accepted by immune system rather than a ****tail, all of which will need to be individually tested and collectively.

Usersteve i belive the lag in share price rise after COVID announcement was due to Hemo flying under the radar and with a £7m market cap may have looked under resourced by retail, fair weather investors to tackle such a challange.
The price didn't seem to take off until i put up an overview of Hemos primary cancer, lupus, autoimmune plans and how their mice fit into the broader COVID picture as well as Hemos direct involvement in developing a treatment and vaccine.

Some may have been suspicious of Hemogenyx's apparent pivot to COVID, but using their mice to identify antibodies to virus x has been on their road map and been worked on for just under a year. So this move is no sudden pivot

Its worth checking out Orgenesis CEO taking about their 3 COVID plans. Hemo are definitely a key player in programme 1, with mice used to identify, test and manufacture COVID antibodies, i would also assume they are supplying mice for program 3 which is a vaccine.

https://youtu.be/ItZ8yc59nds

Poor Graham, I owe him a beer or two haha. Hope he and rest of staff are rewarded with generous stock options.

Co-Diagnostics enjoyed a nice jump on back of issues with Abbott antigen test (50% specificity).

Their q1 report and COVID sales stink, They have MADE 6m tests and recived $18m in sales in total. The are either selling for $3 way below Novacyts £9 or they have stock!!

Co-Diagnostics - $18m sales, 2019 sales $214k, market cap $607m.
Novacyt - £90m sales ($108m), 2019 sales £13m (£15.7m), market cap £233m ($282)

From June Novacyt will be selling approx £100m a month

Herd panic sale over, hello institutions.

https://www.proactiveinvestors.com/companies/amp/news/919723

Co-Diagnostics enjoyed a nice jump on back of issues with Abbott antigen test (50% specificity).

Looking at the q1 report they MADE 6m tests and recived $18m in sales. The are either selling for $3 way below Novacyts £9 or they have stock!!

Co-Diagnostics sales $18m market cap $607m
Novacyt

https://www.proactiveinvestors.com/companies/amp/news/919723

Is a poor photo, neither look like they want to be in it lol. Twitter fun done, now let's see how the mice run

Can i add a large reoccurring French order to your list. Its possible the US OME is lined up to make the two new tests and that's why we've heard nothing. That said we are obviously selling in the States

Haha peck. Am not one for company pumping, but this is actual news and as its related to partner needs little bit of explaining.

Please release the https://youtu.be/X78i13q-atk

Repost my 2020 revenue projection i extrapolated from prior RNS's and annual report

Assuming £9 a test and 10m a month from june
27/02 £0.93m
11/03 £2.3m
13/03 £3.7m
20/03 £8.7m
30/03 £17.8m
17/04 - £37.8m
28/04 - £90m
May - £126.6m (£90m + £36.6m)
June - £216 (10m x £9)
July - £315m
August - £405m
Sept - £495m
Oct - £585m
Nov - £675m
Dec - £765m
Jan - £855m
Feb - £945m
TOTAL £945m + 4x faster D-PCR test volumes

Current market cap £270m

I will buy a genesig q16 for one of my local nursing homes. May be a nice way to directly give back to the community for those who have done well.

https://www.genesig.com/products/9696-the-genesig-q16

Would be swell if the Doc to shared the Orgenesis news.

https://ir.orgenesis.com/press-releases/detail/154

https://www.genesig.com/products/9696-the-genesig-q16